Navigation Links
Cell Therapeutics to Host Investor Day in Milan, Italy on Friday, October 3, 2008
Date:9/10/2008

Company Plans to Provide Update on Key Regulatory Milestones

SEATTLE, Sept. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTICD; and MTA: CTIC) announced today that it will host an investor day in Milan, Italy on October 3, 2008. The investor day will provide an update from executive management on key strategic initiatives and regulatory milestones for the Company. The meeting will be an invitation-only event. A webcast and live teleconference of the event will be available to all investors. Additional event details will provided in the near future.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

E: media@ctiseattle.com

http://www.CellTherapeutics.com/media.htm

Investors Contact:

Ed Bell

T: 206.272.4345

Lindsey Jesch

T : 206.272.4347

F : 206.272.4434

E: invest@ctiseattle.com

http://www.CellTherapeutics.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Halozyme Therapeutics to Present at Upcoming Investor Conferences
2. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
3. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
4. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
5. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
6. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
7. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
8. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
9. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
10. Cell Therapeutics, Inc. Announces Reverse Stock Split
11. Pixel Bridge Works With Anika Therapeutics to Launch New Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  The full interim results will be ... GRS and IGF Society, being held October 15-18, ...
(Date:9/15/2014)... NYHeat drives classical phase transitionsthink solid, liquid, ... when the temperature drops. If phase transitions ... quantum mechanics reigns, subtle fluctuations can dramatically ... the U.S. Department of Energy,s Brookhaven National ... this frigid landscape of absolute zero to ...
(Date:9/15/2014)... University have developed a technique for controlling the surface ... opening the door to a new generation of reconfigurable ... on the fact that the oxide "skin" of the ... acts as a surfactant, lowering the surface tension between ... used a liquid metal alloy of gallium and indium. ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Researchers control surface tension to manipulate liquid metals 2
... MINRAD,International, Inc. (Amex: BUF ) today announced that ... aggregate of $40.0 million of senior,secured convertible notes with ... The notes pay an 8% coupon, have a 3 ... The aggregate net,proceeds of the notes, after deducting the ...
... Biotech and pharma companies,are increasingly utilizing novel ... early in the development cycle to avoid ... and,Biotechnology News (GEN) ( http://www.genengnews.com/ ). By ... early, pharma also has the opportunity to ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
Cached Biology Technology:MINRAD International, Inc. Announces $40.0 Million Private Placement 2MINRAD International, Inc. Announces $40.0 Million Private Placement 3Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
(Date:9/16/2014)... Schizophrenia is associated with increased rates and intensity of ... that the relationship between schizophrenia and smoking stems, in ... to self-medicate symptoms and cognitive impairment associated with the ... issue of Biological Psychiatry , sheds light on ... nicotine receptors in the brain was lower in schizophrenia ...
(Date:9/16/2014)... Proteins are responsible for practically all vital functions ... reactions, forward signals, transport particular substances and control ... that proteins do not function independently of each ... you examine the protein networks, you find many ... Falter-Braun from TUM,s Chair of Plant Systems Biology. ...
Breaking Biology News(10 mins):New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2
... The Society of Interventional Radiology Foundation,s Discovery Campaign, ... invasive medicine into new areas of discovery, announced ... a manufacturer of medical devices, pharmaceuticals and medical ... and is a "Visionary" level supporter. ...
... In the waters off the North Carolina coast, historically-significant ... seafloor, a testament to a relatively unknown chapter in ... shipwrecks are not only important for their cultural value, ... fishes, invertebrates and algal species. Additionally, due to their ...
... by two teams of Army scientists and collaborators has identified ... virus infection. The findings, published online today in separate studies ... for combating one of the world,s most deadly viruses. ... high as 90 percent in humans. The virus is of ...
Cached Biology News:Single protein, key to ebola virus infection, could aid in drug design 2
... Cloning Kits are designed to speed up the ... PCR products, regardless of sequence or type of ... including those that are difficult to clone by ... unstable or code for potentially detrimental proteins can ...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
Biology Products: